(Q37793095)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

main subject

organ transplantation

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Steven A Baroletti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1044-1056

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

Growing roles for the mTOR pathway

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Targeting mTOR in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Xience V everolimus-eluting coronary stent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Drug-eluting stents: a comprehensive appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus: a review of its use in renal and cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Chronic renal allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Chemical modification of rapamycin: the discovery of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Clinical pharmacokinetics of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Ar

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Blood concentrations of everolimus are markedly increased by ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Effect of rifampin on apparent clearance of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Everolimus in pediatric de nova renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.10.1044

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.10.1044

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20874042%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference